Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Oosaki R et al. | Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. | 1997 | Allergy | pmid:9188934 |
Elissalde MH and Beier RC | Stimulation and release of prostaglandins and thromboxane from macrophages by cotton dust associated lipopolysaccharides. | 1990 | Am Ind Hyg Assoc J | pmid:2270833 |
Andersson T et al. | Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. | 2012 | Am J Cardiovasc Drugs | pmid:22631032 |
Leese PT et al. | Valdecoxib does not impair platelet function. | 2002 | Am J Emerg Med | pmid:12098171 |
Jung TT and Juhn SK | Prostaglandins in human cholesteatoma and granulation tissue. | 1988 | Am J Otol | pmid:3177602 |
Mehta P et al. | Plasma concentrations of thromboxane and prostacyclin metabolites in patients with bone tumors. | 1985 | Am J Pediatr Hematol Oncol | pmid:2994511 |
Natarajan G et al. | Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. | 2008 | Am J Perinatol | pmid:18726836 |
Brown HL et al. | Plasma and amniotic fluid prostacyclin and thromboxane in mild pregnancy-induced hypertension. | 1987 | Am J Perinatol | pmid:3566883 |
Satterfield S et al. | Biochemical markers of compliance in the Physicians' Health Study. | 1990 Sep-Oct | Am J Prev Med | pmid:2268456 |
Ingster LM and Feinleib M | Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. | 1998 | Am J Public Health | pmid:9702172 |
Cambria RA et al. | Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. | 1991 | Am Surg | pmid:1847027 |
Montalescot G et al. | Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. | 1990 | Am. Heart J. | pmid:2248190 |
Smith EF and Lefer AM | Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion:efficacy of the nonsteroidal anti-inflammatory agent, naproxen. | 1981 | Am. Heart J. | pmid:7211667 |
Walinsky P et al. | Thromboxane A2 in acute myocardial infarction. | 1984 | Am. Heart J. | pmid:6485997 |
De Caterina R et al. | Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. | 1990 | Am. Heart J. | pmid:2321506 |
Buerke M et al. | Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. | 1995 | Am. Heart J. | pmid:7661062 |
O'Connor KM et al. | The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. | 1989 | Am. Heart J. | pmid:2929400 |
O'Connor KM et al. | Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. | 1986 | Am. Heart J. | pmid:3953390 |
Austin JC et al. | Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. | 1988 | Am. Heart J. | pmid:3344655 |
Arora RR et al. | Laser-induced stimulation of thromboxane B2 synthesis in human blood platelets: role of superoxide radicals. | 1993 | Am. Heart J. | pmid:8381256 |